Overview
Biocon Biologics is a fully integrated biosimilars enterprise committed to making life-changing medicines affordable and accessible to patients everywhere. Guided by our shared purpose to improve global health, we are pursuing our bold ambition to make essential therapies available to all who need them.
Our global scale and fully integrated lab-to-patient model spanning research, development, manufacturing, and commercialization—enables us to address unmet medical needs and improve healthcare outcomes for patients in over 120 countries around the world. With world-class facilities in India and Malaysia, as well as a robust external manufacturing network, we ensure supply chain resilience and consistent quality.
We focus on diseases that affect millions—diabetes, cancer, autoimmune conditions, serious eye disorders, and bone health— and delivering safe, effective, and high-quality biosimilars that meet the highest global standards. Our portfolio includes 10 commercialized biosimilars and a strong pipeline of 10 future launches.
Ranked among the top five global biosimilars players by revenue globally as of FY2025, we are delivering value to patients, partners, and shareholders alike.
Biocon Biologics is a subsidiary of the publicly listed Biocon Limited. Please refer to the Biocon Limited Investor Section for statutory information.
Recent Equity Investments
The Investor Relations section contains information about Biocon Biologics' business for stockholders, potential investors and financial analysts.
